Article Text

PDF
Clinical anti-inflammatory efficacy of arofylline, a new selective phosphodiesterase-4 inhibitor, in dogs with atopic dermatitis
  1. L. Ferrer, DVM, PhD2,
  2. J. Alberola, DVM, PhD1,
  3. M. Queralt, DVM1,
  4. P. Brazis, DVM1,
  5. R. Rabanal, BSc, PhD1,
  6. J. Llenas, BSc, PhD3 and
  7. A. Puigdemont, Pharm,PhD1
  1. 1 Departament de Farmacologia i Terapèutica
  2. 2 Department de Patologia i Producció Animals, Facultat de Veterinaria, Universitat Autònoma de Barcelona, 08193 Bellaterra, Barcelona, Spain
  3. 3 Almirall Prodesfarma, Barcelona, Spain

Abstract

Forty atopic dogs were studied for 28 days after the oral administration of four randomised treatments: (A) arofylline (1 mg/kg) twice daily for four weeks; (B) prednisone (0.5 mg/kg) twice daily for the first week, once a day during the second week and every 48 hours for the remaining two weeks; (C) prednisone following the same protocol but at a dose of 0-25 mg/kg; or (D) arofylline (1 mg/kg) twice daily for four weeks plus prednisone (0.25 mg/kg) following the same protocol as in (B) and (C). The degree of pruritus and skin lesions and the side effects were evaluated and graded from 0 to 3 before and weekly during the treatments. In all cases there was a progressive clinical improvement in the clinical signs, with no statistical differences among the four treatments. However, many of the dogs treated with arofylline vomited and had adverse gastrointestinal signs.

    Statistics from Altmetric.com

      Request permissions

      If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.